IgA Nephropathy
Phase 3 VISIONARY trial data showed sibeprenlimab helps achieve significant proteinuria reduction in IgAN.
Treatment effects of nefecon were consistent independent of baseline eGFR among patients with IgAN.
Infliximab therapy for Crohn’s disease is linked to a high risk for IgAN, a study found.
Research identified the optimal biomarker combination to predict interstitial fibrosis surface in IgA nephropathy.
Long-term data demonstrated that zigakibart reduced proteinuria and stabilized kidney function of patients with IgAN.
Moderate-to-severe chronic arteriolar lesions were found to be independent risk factors for adverse renal prognosis in IgAN.
A study found low rates of IgAN in the EU, but lower biopsy rates during the COVID-19 pandemic may have delayed diagnoses.
Three kidney organizations will develop a consensus framework for Centers of Excellence in Glomerular Disease Care.
Nefecon can safely be used to treat severe renal impairment and lowers proteinuria in patients with IgAN.
Proteinuria trajectory is a major predictor of disease progression in children and adults with IgAN, a study found.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.